OncoMatch/Clinical Trials/NCT06974110
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Is NCT06974110 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MOMA-341 and Irinotecan for advanced solid tumor.
Treatment: MOMA-341 · Irinotecan · Immunotherapy — This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Endometrial Cancer
Colorectal Cancer
Gastric Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy
Participants must have previously received and progressed on an anti-PD-(L)1-based regimen, unless ineligible or in a region without access to anti-PD-(L)1 therapies
Lab requirements
Blood counts
adequate organ function per local labs
Kidney function
adequate organ function per local labs
Liver function
adequate organ function per local labs
Adequate organ function per local labs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Investigative Site #128 · Tampa, Florida
- Investigative Site #120 · Detroit, Michigan
- Investigative Site #110 · St Louis, Missouri
- Investigative Site #131 · Raleigh, North Carolina
- Investigative Site #121 · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify